FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
NeuWire Medical has received FDA Investigational Device Exemption (IDE) approval to proceed with STROKE-REWIRE, a pivotal clinical study evaluating its investigational neurostimulation device for the treatment of chronic ischemic
“For people living with upper-limb dysfunction after
KEY FACTS
• Drug/Device: NeuWire Medical neurostimulation device
• Class: Investigational Class III medical device
• Indication: Chronic ischemic stroke recovery
• Regulatory Action: FDA IDE approval granted
• Trial Name: STROKE-REWIRE (pivotal study)
• Trial Phase: Pivotal (PMA-enabling)
• Geography: United States
Trial and Regulatory Overview. The FDA's IDE approval authorizes NeuWire Medical to initiate STROKE-REWIRE as a pivotal study — the regulatory phase typically required to support a Premarket Approval (PMA) application for Class III medical devices. An IDE allows a device under investigation to be used in a clinical study to collect the safety and efficacy data needed for regulatory review.2
Clinical Context: The Burden of Chronic Ischemic Stroke. Ischemic stroke accounts for approximately 87% of all strokes in the US, with an estimated 795 000 Americans experiencing a new or recurrent stroke each year.3 Among survivors, a substantial proportion experience persistent neurological deficits, including motor impairment, aphasia, and functional disability, that extend well beyond the acute and subacute phases of recovery.
The chronic phase of ischemic stroke, generally defined as beginning 6 months or more after the index event, represents a period during which spontaneous neurological recovery substantially plateaus. Standard rehabilitative approaches, including physical, occupational, and speech therapy, offer incremental benefit for some patients, but no device-based or pharmacologic intervention has achieved broad regulatory approval specifically targeting chronic-phase motor recovery. This gap represents a meaningful unmet clinical need.
Device and Mechanism Background. NeuWire Medical's investigational platform is described as a neurostimulation-based approach to promoting neurological recovery in chronic ischemic stroke. Neurostimulation therapies, including epidural cortical stimulation and vagus nerve stimulation paired with rehabilitation, have been explored in prior stroke recovery research as mechanisms to promote neuroplasticity, the brain's capacity to reorganize functional pathways following injury.
Interpretive Framing. IDE approval is a regulatory authorization to conduct human trials — it does not constitute evidence of device safety or efficacy, nor does it predict eventual FDA marketing authorization. The STROKE-REWIRE pivotal designation suggests NeuWire intends the trial data to directly support a PMA submission, which itself requires demonstration of reasonable assurance of safety and effectiveness under 21 CFR Part 814.2
The chronic stroke recovery space has seen prior device programs that demonstrated encouraging early signals but faced challenges in confirmatory trials. Investigators and potential enrolling centers should approach the forthcoming trial with standard scientific rigor.
References
